ClinicalTrials.gg
CompletedNCT06772805Updated Jan 14, 2025

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)

A Phase 1 interventional study of Nemtabrutinib in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.
  • Registered 1 year 5 months after the study started (first participant enrolled Jul 2023, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The goal of the study is to learn what happens to levels of nemtabrutinib in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given under fasted (on an empty stomach) and fed (after a high-fat meal) conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria include, but are not limited to:

  • Is in good health based on medical history, physical examination, vital sign measurements, and (ECGs) performed before randomization
  • Has a (BMI) 18 to 32 kg/m\^2 (inclusive)

Exclusion criteria

Exclusion Criteria:

Exclusion criteria include, but are not limited to:

  • Has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer ()
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Nemtabrutinib Treatment A

    Participants receive a single dose of nemtabrutinib on Day 1 under fasted conditions (on an empty stomach after a 10-hour overnight fast)

    Drug: Nemtabrutinib

  • Experimental
    Nemtabrutinib Treatment B

    Participants receive a single dose of nemtabrutinib on Day 1 under fed conditions (after a high-fat meal)

    Drug: Nemtabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Nemtabrutinib

    Blood samples will be collected to determine the AUC0-inf of nemtabrutinib in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 2 weeks postdose)

Secondary outcomes

  1. Time Taken for the Drug to Appear in the Systemic Circulation Following Administration (Tlag) of Nemtabrutinib

    Blood samples will be collected to determine the Tlag of nemtabrutinib in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 2 weeks postdose)

  2. Apparent Terminal Elimination Half-Life (t1/2) of Nemtabrutinib

    Blood samples will be collected to determine the t1/2 of nemtabrutinib in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 2 weeks postdose)

  3. Apparent Total Plasma Clearance (CL/F) of Nemtabrutinib

    Blood samples will be collected to determine the CL/F of nemtabrutinib in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 2 weeks postdose)

  4. Apparent Volume of Distribution During Terminal Elimination Phase (Vz/F) of Nemtabrutinib

    Blood samples will be collected to determine the Vz/F of nemtabrutinib in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 2 weeks postdose)

  5. Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Nemtabrutinib

    Blood samples will be collected to determine the AUC0-last of nemtabrutinib in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 2 weeks postdose)

  6. Maximum Observed Concentration (Cmax) of Nemtabrutinib

    Blood samples will be collected to determine the Cmax of nemtabrutinib in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 2 weeks postdose)

  7. Time of the Maximum Observed Concentration (Tmax) of Nemtabrutinib

    Blood samples will be collected to determine the Tmax of nemtabrutinib in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 2 weeks postdose)

  8. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 30 days

  9. Number of Participants Who Discontinue the Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 14 days

07

Study locations

1 site
  • Labcorp Clinical Research Unit Inc. (Site 0001)
    Honolulu, Hawaii 96813, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Dec 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 14, 2025
StartActual
Jul 24, 2023
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06772805
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Jul 24, 2023
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Last update
Jan 14, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARQ531

Start the discussion